Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - YiFan Pharmaceutical's wholly-owned subsidiary, SciGen Pte. Ltd., has been granted a market registration approval by HSA [1] - The approved product, racemic norepinephrine injection solution, is used for blood pressure control in adults experiencing severe acute hypotension [1] - The drug is designed to elevate blood pressure levels in critical situations [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2026-010 亿帆医药股份有限公司 关于重酒石酸去甲肾上腺素注射用浓溶液获得新加坡注册 批文的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司SciGen Pte. Ltd.于 近日收到新加坡卫生科学局（Health Sciences Authority）（以下简称"HSA"） 核准签发的上市注册批文，批准公司化药产品重酒石酸去甲肾上腺素注射用浓溶 液在新加坡上市销售。现将相关情况公告如下： 一、药品注册主要信息 的子公司生产线通过新加坡PIC/S GMP认证，标志着公司质量管理体系和生产能 力再次得到国际权威认证机构的认可，为公司境内化药注射剂产品拓展国际市场 提供了坚实保障。 3、剂型：注射剂 4、规格：4mg/4mL 5、生产厂家：合肥亿帆生物制药有限公司 6、注册编号：SIN17453P 二、产品简介 重酒石酸去甲肾上腺素注射用浓溶液适用于成人严重、急性低血压状态的血 压控制（可提升血压水平）。2023年3月，该产品在国内获批上市。公司于2 ...

Core Viewpoint - The company, Yifan Pharmaceutical, is in the early stages of market introduction for its product, Yilishu, in the U.S. and is not yet experiencing significant sales volume [1] Group 1 - The procurement volume of Yilishu by its U.S. partner is determined by agreements and orders, which may not directly correlate with actual end-user sales [1] - Yilishu has been on the U.S. market for less than a year and is still in the initial ramp-up phase of its introduction [1]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Core Viewpoint - The company has approved a comprehensive credit financing limit of up to RMB 650 million and a guarantee limit of up to RMB 600 million for itself and its subsidiaries, aimed at supporting business operations and development [2][5]. Group 1: Guarantee Adjustment Situation - The company has adjusted the unused guarantee limits of its subsidiaries, transferring a total of RMB 16 million to its wholly-owned subsidiary Hefei Yifan Pharmaceutical Co., Ltd. (合肥亿帆) [3]. - After the adjustment, the guarantee limits for Sichuan Defeng Pharmaceutical Co., Ltd., Anqing Xinfuhua Chemical Co., Ltd., and Xinfuhua Technology Co., Ltd. have been reduced to zero, while the limit for Hefei Yifan has increased from RMB 88 million to RMB 104 million [3]. Group 2: Guarantee Overview - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank Hefei Branch, agreeing to provide a joint liability guarantee for Hefei Yifan's debts, with a maximum guarantee amount of RMB 10 million [4]. - The guarantee is valid for the duration of the loans or financing agreements under the credit agreement, extending three years beyond the maturity of each loan [9]. Group 3: Financial and Operational Context - Hefei Yifan, established on September 9, 2022, is a wholly-owned subsidiary of the company, with a registered capital of RMB 100 million and involved in various pharmaceutical and medical-related activities [6][7]. - The company has confirmed that Hefei Yifan is not a dishonest executor and has the capability to repay its debts [10]. Group 4: Cumulative Guarantee Situation - As of the report date, the total external guarantee balance of the company and its subsidiaries is RMB 5.132 billion, accounting for 60.22% of the company's audited net assets for 2024 [11].

Group 1 - The company has approved a total credit limit of up to RMB 650 million and a guarantee limit of up to RMB 600 million for itself and its subsidiaries [2][5] - The company has reallocated unused guarantee limits from subsidiaries to its wholly-owned subsidiary Hefei Yifan Pharmaceutical Co., increasing its guarantee limit from RMB 88 million to RMB 104 million [3] - As of the announcement date, the remaining guarantee balance for Hefei Yifan is RMB 93.6 million [3] Group 2 - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank Hefei Branch, agreeing to provide a joint liability guarantee for Hefei Yifan's debts, with a maximum guarantee amount of RMB 10 million [4][7] - The guarantee covers loans and other credit balances within the approved credit limit, including related interest and fees [8] - The guarantee period extends until the expiration of each loan or financing agreement plus an additional three years [8] Group 3 - Hefei Yifan is a wholly-owned subsidiary of the company, established on September 9, 2022, with a registered capital of RMB 100 million [6] - The subsidiary is not listed as a dishonest executor and has stable operations, indicating its ability to repay debts [9][10] - The cumulative external guarantee balance after this new guarantee is RMB 5.132 billion, accounting for 60.22% of the company's audited net assets for 2024 [10]

Core Viewpoint - Yifan Pharmaceutical (002019) announced that the company and its controlling subsidiaries have not provided guarantees for units outside the scope of the consolidated financial statements, nor do they have overdue guarantees, litigation-related guarantee amounts, or losses due to judgments against guarantees [1] Group 1 - The company has not provided any guarantees for units outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company [1] - The company has not incurred any losses due to judgments related to guarantees [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2026-009 亿帆医药股份有限公司 关于在下属子公司之间调剂担保额度及为全资子公司提供担保 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保额度调剂情况 亿帆医药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开的第 八届董事会第十六次会议及 2025 年 5 月 20 日召开的 2024 年年度股东会，均审 议通过了《关于公司及控股公司向金融机构申请授信额度及公司合并报表范围内 担保额度的议案》，同意公司及控股公司向各家金融机构申请总额度不超过人民 币 650,000 万元（或等值外币）的综合授信融资，申请纳入公司合并报表范围内 的公司相互提供担保，担保额度合计不超过人民币 600,000 万元（或等值外币）， 授权期限为自 2024 年年度股东会审议通过之日起 12 个月内有效，额度范围内可 循环使用。 上述内容具体详见公司于 2025 年 4 月 28 日及 2025 年 5 月 21 日在巨潮资讯 网上披露的《第八届董事会第十六次会议决议公告》（公告编号： ...

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]